ALUMIS INC (ALMS) Fundamental Analysis & Valuation

NASDAQ:ALMS • US0223071020

Current stock price

22.94 USD
+0.23 (+1.01%)
At close:
22.5 USD
-0.44 (-1.92%)
After Hours:

This ALMS fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. ALMS Profitability Analysis

1.1 Basic Checks

  • ALMS had negative earnings in the past year.
  • ALMS had a negative operating cash flow in the past year.
ALMS Yearly Net Income VS EBIT VS OCF VS FCFALMS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2022 2023 2024 2025 -100M -200M -300M -400M

1.2 Ratios

  • ALMS's Return On Assets of -59.07% is on the low side compared to the rest of the industry. ALMS is outperformed by 68.23% of its industry peers.
  • With a Return On Equity value of -80.76%, ALMS is not doing good in the industry: 61.46% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -59.07%
ROE -80.76%
ROIC N/A
ROA(3y)-106.1%
ROA(5y)N/A
ROE(3y)-207.7%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ALMS Yearly ROA, ROE, ROICALMS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2022 2023 2024 2025 -100 -200 -300 -400

1.3 Margins

  • ALMS does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ALMS Yearly Profit, Operating, Gross MarginsALMS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2022 2023 2024 2025 -500 -1K -1.5K

8

2. ALMS Health Analysis

2.1 Basic Checks

  • ALMS does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • ALMS has more shares outstanding than it did 1 year ago.
  • ALMS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
ALMS Yearly Shares OutstandingALMS Yearly Shares OutstandingYearly Shares Outstanding 2022 2023 2024 2025 20M 40M 60M 80M 100M
ALMS Yearly Total Debt VS Total AssetsALMS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2022 2023 2024 2025 100M 200M 300M 400M

2.2 Solvency

  • An Altman-Z score of 9.42 indicates that ALMS is not in any danger for bankruptcy at the moment.
  • With an excellent Altman-Z score value of 9.42, ALMS belongs to the best of the industry, outperforming 84.90% of the companies in the same industry.
  • ALMS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 9.42
ROIC/WACCN/A
WACC9.18%
ALMS Yearly LT Debt VS Equity VS FCFALMS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2022 2023 2024 2025 0 200M -200M

2.3 Liquidity

  • A Current Ratio of 4.34 indicates that ALMS has no problem at all paying its short term obligations.
  • ALMS's Current ratio of 4.34 is fine compared to the rest of the industry. ALMS outperforms 61.46% of its industry peers.
  • A Quick Ratio of 4.34 indicates that ALMS has no problem at all paying its short term obligations.
  • ALMS has a better Quick ratio (4.34) than 64.06% of its industry peers.
Industry RankSector Rank
Current Ratio 4.34
Quick Ratio 4.34
ALMS Yearly Current Assets VS Current LiabilitesALMS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2022 2023 2024 2025 100M 200M 300M

3

3. ALMS Growth Analysis

3.1 Past

  • ALMS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 45.49%, which is quite impressive.
EPS 1Y (TTM)45.49%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-308.7%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • Based on estimates for the next years, ALMS will show a quite strong growth in Earnings Per Share. The EPS will grow by 14.68% on average per year.
  • Based on estimates for the next years, ALMS will show a very strong growth in Revenue. The Revenue will grow by 100.85% on average per year.
EPS Next Y41.21%
EPS Next 2Y22.23%
EPS Next 3Y16.28%
EPS Next 5Y14.68%
Revenue Next Year-72.5%
Revenue Next 2Y-3.26%
Revenue Next 3Y88.8%
Revenue Next 5Y100.85%

3.3 Evolution

ALMS Yearly Revenue VS EstimatesALMS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2025 2026 2027 2028 2029 2030 2031 2032 2033 500M 1B 1.5B
ALMS Yearly EPS VS EstimatesALMS Yearly EPS VS EstimatesYearly EPS VS Estimates 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 2 -2 -4 -6 -8

0

4. ALMS Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for ALMS. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ALMS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ALMS Price Earnings VS Forward Price EarningsALMS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ALMS Per share dataALMS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 -4

4.3 Compensation for Growth

  • A more expensive valuation may be justified as ALMS's earnings are expected to grow with 16.28% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y22.23%
EPS Next 3Y16.28%

0

5. ALMS Dividend Analysis

5.1 Amount

  • No dividends for ALMS!.
Industry RankSector Rank
Dividend Yield 0%

ALMS Fundamentals: All Metrics, Ratios and Statistics

ALUMIS INC

NASDAQ:ALMS (4/9/2026, 5:14:07 PM)

After market: 22.5 -0.44 (-1.92%)

22.94

+0.23 (+1.01%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)03-19
Earnings (Next)05-12
Inst Owners43.39%
Inst Owner Change0%
Ins Owners0.73%
Ins Owner Change0%
Market Cap2.86B
Revenue(TTM)24.05M
Net Income(TTM)-243.32M
Analysts88.24
Price Target40.35 (75.89%)
Short Float %11.26%
Short Ratio5.67
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-3.83%
Min EPS beat(2)-13.42%
Max EPS beat(2)5.77%
EPS beat(4)1
Avg EPS beat(4)-11.82%
Min EPS beat(4)-20.07%
Max EPS beat(4)5.77%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-24.45%
Min Revenue beat(2)-28.51%
Max Revenue beat(2)-20.39%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)11.2%
PT rev (3m)99.2%
EPS NQ rev (1m)7.12%
EPS NQ rev (3m)3.54%
EPS NY rev (1m)0%
EPS NY rev (3m)-0.24%
Revenue NQ rev (1m)-39.19%
Revenue NQ rev (3m)-43.99%
Revenue NY rev (1m)4.72%
Revenue NY rev (3m)25.7%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 118.91
P/FCF N/A
P/OCF N/A
P/B 9.49
P/tB 11.42
EV/EBITDA N/A
EPS(TTM)-5.5
EYN/A
EPS(NY)-3.23
Fwd EYN/A
FCF(TTM)-2.97
FCFYN/A
OCF(TTM)-2.96
OCFYN/A
SpS0.19
BVpS2.42
TBVpS2.01
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -59.07%
ROE -80.76%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-106.1%
ROA(5y)N/A
ROE(3y)-207.7%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.06
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 18.68%
Cap/Sales 2.72%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.34
Quick Ratio 4.34
Altman-Z 9.42
F-Score4
WACC9.18%
ROIC/WACCN/A
Cap/Depr(3y)141.34%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)45.49%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-308.7%
EPS Next Y41.21%
EPS Next 2Y22.23%
EPS Next 3Y16.28%
EPS Next 5Y14.68%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-72.5%
Revenue Next 2Y-3.26%
Revenue Next 3Y88.8%
Revenue Next 5Y100.85%
EBIT growth 1Y-50.89%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year16.49%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-44.14%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-44.87%
OCF growth 3YN/A
OCF growth 5YN/A

ALUMIS INC / ALMS Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for ALUMIS INC?

ChartMill assigns a fundamental rating of 3 / 10 to ALMS.


What is the valuation status for ALMS stock?

ChartMill assigns a valuation rating of 0 / 10 to ALUMIS INC (ALMS). This can be considered as Overvalued.


Can you provide the profitability details for ALUMIS INC?

ALUMIS INC (ALMS) has a profitability rating of 0 / 10.